Translational Research on Heart Failure and Arrhythmias

translational-research-heart-failureResearch overview

Heart failure, sudden death, and atrial fibrillation are often manifestations of cardiomyopathies and chronic cardiac damage. We study the effects of genetic factors for the development of heart failure, atrial fibrillation, and sudden death. We use molecular biology, imaging, and physiological techniques to identify mechanisms leading to these diseases, work on novel ways to develop and validate personalized approaches to diagnose and treat patients with these conditions, and test interventions in experimental models and in clinical trials.

Our research group

We use cellular and integrated physiological measurements, molecular biology, and imaging techniques to characterise heart function in transgenic models. These allow us to identify molecular mechanisms of cardiac dysfunction (e.g. in inherited cardiomyopathies) and help to delineate new therapeutic targets for personalized treatment of heart failure and arrhythmias.

Our group works closely with other research groups on campus and in the two major NHS trusts (UHB and SWBH) in Birmingham. We maintain research contacts with the German Atrial Fibrillation NETwork and with the Medical Faculty at the University of Münster, and collaborate with professional organisations and research networks in Britain and Europe. Together with these partners, we explore possibilities to translate new insights into hypotheses that can be tested in clinical trials and/or in biobanks, with the final goal to improve treatment of patients suffering from heart failure, atrial fibrillation, and/or to prevent sudden death using personalized approaches to diagnosis and therapy.

Current projects

  • Deciphering the genetic topology of atrial fibrillation
  • Understanding the function of pitx2 in the left atrium
  • Translating mechanisms of AF into new diagnostic and therapeutic modalities
  • Sodium channel dysfunction and its contribution to heart failure and arrhythmias
  • Understanding the relevance of desmosomal proteins for right heart function and failure
  • Improving outcomes by early rhythm control therapy in atrial fibrillation

Recent publications


Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet. 2017 doi: 10.1016/S0140-6736(17)31072-3. 

Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.  Am Heart J. 2017 doi: 10.1016/j.ahj.2017.04.015.   

Di Biase L, Callans D, Hæusler KG, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017 Jan;19(1):132-138. doi: 10.1093/europace/euw368. 

Cleland JGF, Bunting KV,  Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Bohm M, Andersson B, Kjekshus J, Packer M , Rigby A, Rosano G, Wedel H, Hjalmarson A, Wikstrand J, Kotecha D*.  Beta-blockers for heart failure with reduced, mid-range and preserved ejection fraction: An individual patient-level analysis of double-blind randomised trials.  Eur Heart J. 2017; 10.1093/eurheartj/ehx564.  

Kotecha D*, Kirchhof P.  ESC Apps for Atrial Fibrillation. Eur Heart J (Cardiopulse).  2017;38:2643-2645.  

Kotecha D*, Chua W, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P.  European Society of Cardiology (ESC) smartphone and tablet applications for patients with atrial fibrillation and their healthcare providers.  Europace. 2017; 10.1093/europace/eux299.   

Kotecha D, Breithardt G, Camm AJ, Lip GYHL, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, et al.  Integrating new approaches to atrial fibrillation management: The 6th Joint Consensus Conference of the Atrial Fibrillation Network (AFNET) and the European Heart Rhythm Association (EHRA). Europace. 2017; 10.1093/europace/TBC.  

Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA*. Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Fail Rev. 2017;10.1007/s10741-017-9640-5.  

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, , van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson A, Kjekshus J, Cleland JGF*.  Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.  J Am Coll Cardiol. 2017;69:2885-2896. 

Kotecha D*, Mohammed M, Shantsila E, Popescu BA, Steeds RS.  Is echocardiography valid and reproducible in patients with atrial fibrillation? A systematic review.  Europace. 2017;10.1093/europace/eux027.  

Lane DA*, Skøjth F, Larsen TB, Lip GYH, Kotecha D.  Temporal trends in atrial fibrillation incidence, comorbidity and mortality: comprehensive linked data from primary care. J Am Heart Assoc. 2017; 2017;6:e005155. 

Kotecha D*, Altman DG, Rosano G, Flather MD.  Observational Versus Randomized: Sliding Toward Nonevidence-Based Medicine [letter].  JACC Heart Fail. 2017;5:395-396.  

von Lueder T*, Kotecha D, Atar D, Hopper I.  Neurohormonal Blockade in Heart Failure. Cardiac Failure Review. 2017;3:19-24.  

Kotecha D, Kirchhof P. What’s new in the 2016 ESC Guidelines on atrial fibrillation? Eur Heart J (Cardiopulse). 2016;37:2851-2. 

Kotecha D*, Ahmed A, Calvert M, Lencioni M, Terwee C, Lane DA.  Evaluation of patient-reported outcomes for quality of life assessment in atrial fibrillation: A systematic review. PLOS one. 2016;11:e0165790. 

Kotecha D, Lam CS, van Veldhuisen DJ, van Gelder IC, Voors AA, Rienstra M*.  Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins.  J Am Coll Cardiol. 2016;68:2217-28. 

Kotecha D*.  Magnesium for Atrial Fibrillation, Myth or Magic?  Circ Arrhythm Electrophysiol. 2016;9: DOI: 10.1161/CIRCEP.116.004521.  

Kirchhof P*, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella Pericas M, Diener H, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016;37:2893-2962.  PMID: 27567408.  Impact factor 20.213.

Also published in:

Europace. 2016;18:1609-1678.  PMID: 27567465.  Impact factor 4.530.
Eur J Cardiothorac Surg. 2016;50:e1-e88.  PMID: 27663299.  Impact factor 3.759.
Kardiologia polska 2016;74:1359-1469.  PMID: 28009037.  Impact factor 1.341.
Rev Esp Cardiol 2017;70:50.  PMID: 28038729.  Impact factor 4.485.

Castleman J, Ganapathy R, Lip GYH, Steeds RS, Kotecha D*.  Cardiac structure and function in hypertensive disorders of pregnancy: a systematic review. Circ Cardiovasc Imaging.  2016;9: e004888. 

Kotecha D*, Manzano L, Packer M, Rosano G, Collins P, Krum H, Holmes J, Altman DG, Wikstrand J, Coats AJS, Cleland JGF, von Lueder TG, Rigby A, Shibata MC, Andersson B, Kirchhof P, Wedel H, Lip GYH, Flather MD.  Age and gender differences in treatment efficacy and tolerability: The Beta-blockers in Heart Failure Collaborative Group.  BMJ.  2016;353:i1855. 

Kotecha D*. Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients (Letter). Int J Cardiol.  2016;214:516-7.  

Ziff OJ, Kotecha D*. Digoxin: the good and the bad.  Trends Cardiovasc Med.  2016;26:585-95. 

Hopper I, Kotecha D, Lee Chin K, Mentz RJ, von Lueder TG*.  Comorbidities in heart failure: Are there gender differences?  Curr Heart Fail Rep.  2016;13:1-12.    

Kotecha D*, Chudasama R, Lane DA, Kirchhof P, Lip GYH.  Atrial fibrillation and heart failure: A systematic review and meta-analysis of clinical outcomes in reduced versus preserved ejection fraction.  Int J Cardiol2016;203:660-6. 

Kotecha D*, Piccini JP. Atrial fibrillation in heart failure. What should we do? Eur Heart J. 2015:46:3250-7

Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D*.  Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data.  BMJ. 2015;351:h4451. 

Senoo K, Lip GYH*, Lane DA, Büller HR, Kotecha D.  Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial.  Stroke. 2015;46:2523-8. 

Kotecha D*, von Leuder TG.  Qualifying the use of common cardiovascular drugs in cardiology: Time to think again about beta-blockers?  Circ J. 2015;79:517-518. 

Kotecha D, Banerjee A, Lip GYH*.  Increased Stroke Risk in Atrial Fibrillation Patients With Heart Failure: Does Ejection Fraction Matter?  Stroke. 2015;46:608-609. 

Kotecha D*, Kirchhof P.  Rate and rhythm control have comparable effects on mortality and stroke in atrial fibrillation but better data are needed.  Evid Based Med. 2014;19:222-223. 

Kotecha D*, Lip GYH.  Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm.  Hypertens Res. 2013;36:854-855. 


Kotecha D*, Manzano L, Altman DG, Krum H, Erdem G, Williams N, Flather MD.   Individual Patient Data Meta-Analysis of Beta-Blockers in Heart Failure: Rationale and Design.  Syst Rev. 2013;2:7. 


Kotecha D*, New G, Collins P, Eccleston D, Krum H, Pepper J, Flather MD.  Radial Artery Pulse Wave Analysis for Non-invasive Assessment of Coronary Artery Disease.  Int J Cardiol. 2013;167:917-924. 

Kotecha D*, New G, Flather M, Eccleston D, Pepper J, Krum H.  Five-minute heart rate variability can predict obstructive angiographic coronary disease.  Heart. 2012;98:395-401. 

Kotecha D*, Ngo K, Walters J, Manzano L, Palazzuoli A, Flather M.  Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials.  Am Heart J. 2011:161:822-831. 

Kotecha D*, Flather M, McGrady M, Pepper J, New G, Krum H, Eccleston D.  Contemporary predictors of coronary artery disease in patients referred for angiography.  Eur J Cardiovasc Prev Rehabil (now Eur J Prev Cardiol).  2010:17: 280-288. 

Flather M, Kotecha D. Chapter 6: Thienopyridines in Stable Coronary Disease; from Antithrombotic Drug Therapy in Cardiovascular Disease. Humana Press. 2010.

Ngo K, Kotecha D*, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M.  Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients.  Cochrane DB Syst Rev. 2010:(1): CD007613. 

Cohen-Solal A, Kotecha D*, van Veldhuisen D, Bohm M, Coats A, Roughton M, Babalis D, Poole-Wilson P, Tavazzi L, Flather M.  Efficacy & safety of nebivolol in elderly heart failure patients with impaired renal function.  Eur J Heart Fail.  2009;11(9):872-80. 

Kirchhof P, Fabritz L. Anterior T-Wave Inversion Does Not Convey Short-Term Sudden Death Risk: Inverted Is the New Normal.  J Am Coll Cardiol. 2017 Jan 3;69(1):10-12. doi: 10.1016/j.jacc.2016.11.011. No abstract available.

Schnabel RB, Pecen L, Ojeda FM, Lucerna M, Rzayeva N, Blankenberg S, Darius H, Kotecha D, Caterina R, Kirchhof P. Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. Heart, published on line February 2017.

Syeda F, Kirchhof P, Fabritz L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol. Published on line 19 Feb 2017.

Kirchhof P. The Future of atrial fibrillation management. Integrated care and stratified therapy. Lancet, published on line April 2017.

Ponomaryov T, Payne H, Fabritz L, Wagner DD, Brill A. 2017.  Mast Cells Granular Contents Are Crucial for Deep Vein Thrombosis in Mice. Circulation Research.

Kotecha D, Calvert M, Deeks JJ, Griffith M, Kirchhof P, Lip GYH, Mehta S, Slinn G, Stanbury M, Steeds RP, Townend JN. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open. 2017: DOI: 10.1136/bmjopen-2016-015099

Di Biase L, Callans D, Georg Haeusler K, Hindricks G, Al-Khalidi H, Mont L, Cosedis Nielsen J, Piccini JP, Schotten U, Kirchhof P. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Europace. 2017;19:132-8. doi:10.1093/europace/euw368 

Holmes AP, Kirchhof P. Pitx2 Adjacent Noncoding RNA: A New, Long, Noncoding Kid on the 4q25 Block. Circ Arrhythm Electrophysiol. 2016;9, published on line 25 January 2016.

Syeda F, Holmes AP, YuTY, Tull S, Kuhlmann SM, Pavlovic D, Betney D, Riley G, Kucera JP, Jousset F, de Groot JR, Rohr S, Brown NA , Fabritz L, Kirchhof P. 2016. PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.  Journal of the American College of Cardiology. Vol. 68, issue 17, 2016, p. 1881-1894.

Syeda F, Holmes AP, Yu TY, Tull S, Kuhlmann SM, Pavlovic D, Betney D, Riley G, Kucera JP, Jousset F, de Groot JR, Rohr S, Brown N, Fabritz L, Kirchhof P. PITX2 modulates atrial membrane potential and reduced PITX2 potentiates the antiarrhythmic effects of sodium-channel blockers. J Am Coll Cardiol. 2016;68:59-72; doi: 10.1016/j.jacc.2016.07.766.

Ackers-Johnson M, Li PY, Holmes AP, O'Brien SM, Pavlovic D, Foo RS  A Simplified, Langendorff-Free Method for Concomitant Isolation of Viable Cardiac Myocytes and Non-Myocytes from the Adult Mouse Heart. Circulation Research; 2016; 119(8):909-20.

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kaab S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment. Nat Rev Cardiol. 2016;13:230-7.

Kirchhof P, Fabritz L. Can biomarkers balance stroke and bleeding risk? Lancet. 2016;10.1016/S0140-6736(16)30121-0 

Shantsila E, Haynes R, Calvert M, Fisher J, Kirchhof P, Gill PS, Lip GY. IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial.BMJ Open. 2016;6:e012241.

Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. Am Heart J. 2016;179:59-68.

Oto E, Okutucu S, Katircioglu-Ozturk D, Guvenir HA, Karaagaoglu E, Borggrefe M, Breithardt G, Goette A, Ravens U, Steinbeck G, Wegscheider K, Oto A, Kirchhof P. Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. Europace. published on line July 2016.

Holmes AP, Yu TY, Tull S, Syeda F, Kuhlmann SM, O'Brien SM, Patel P, Brain KL, Pavlovic D, Brown NA, Fabritz L, Kirchhof P. A Regional Reduction in Ito and IKACh in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity. PLoS One. 2016;11:e0154077.

Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJ, Cleland JG, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GY, van Veldhuisen DJ, Shibata MC, Wedel H, Bohm M, Flather MD, Beta-Blockers in Heart Failure Collaborative G. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855

Haeusler KG, Kirchhof P, Heuschmann PU, Laufs U, Busse O, Kunze C, Thomalla G, Nabavi DG, Rother J, Veltkamp R, Endres M. Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. Am Heart J. 2016;172:19-25.

Fabritz L. The power of P in the elderly: Small biphasic wave, big impact. Heart Rhythm. 2015 Nov 18. pii: S1547-5271(15)01434-4. doi: 10.1016/j.hrthm.2015.11.027. [Epub ahead of print] 

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace. 2015 Oct 18. pii: euv304. [Epub ahead of print] Review.

Schotten U, Hatem S, Ravens U, Jaïs P, Müller FU, Goette A, Rohr S, Antoons G, Pieske B, Scherr D, Oto A, Casadei B, Verheule S, Cartlidge D, Steinmeyer K, Götsche T, Dobrev D, Kockskämper J, Lendeckel U, Fabritz L, Kirchhof P, Camm AJ; EUTRAF investigators. The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results. Europace. 2015 Oct;17(10):1457-66. doi: 10.1093/europace/euv252. Epub 2015 Sep 12. Review.

Poulet C, Wettwer E, Grunnet M, Jespersen T, Fabritz L, Matschke K, Knaut M, Ravens U. Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation. PLoS One. 2015 Jun 29;10(6):e0131432. doi: 10.1371/journal.pone.0131432. eCollection 2015.

Zhang M, Schulte JS, Heinick A, Piccini I, Rao J, Quaranta R, Zeuschner D, Malan D, Kim KP, Röpke A, Sasse P, Araúzo-Bravo M, Seebohm G, Schöler H, Fabritz L, Kirchhof P, Müller FU, Greber B. Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation. Stem Cells. 2015 May;33(5):1456-69. doi: 10.1002/stem.1964.

Kirchhof P, Tal T, Fabritz L, Klimas J, Nesher N, Schulte JS, Ehling P, Kanyshkova T, Budde T, Nikol S, Fortmueller L, Stallmeyer B, Muller FU, Schulze-Bahr E, Schmitz W, Zlotkin E, Kirchhefer U. First Report on an Inotropic Peptide Activating TTX-Sensitive, "Neuronal" Sodium Currents in the Heart. Circ Heart Fail 2015; 8: 79-88.

Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, on behalf of the Beta-Blockers in Heart Failure Collaborative G. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014; 384: 2235-2243.

Yu TY, Syeda F, Holmes A, Osborne B, Dehghani H, Brain KL, Kirchhof P, Fabritz L. An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials. Prog Biophys Mol Biol; 2014;115:340-8.

Pavlovic D The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin Prac; 2014; 128(1-2):11-21. 

Fabritz L, Franz MR, Carmeliet E and Kirchhof P (2014) To the Editor-Propranolol, aβ-adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect. Heart Rhythm11(3):e1

Fabritz L and Kirchhof P (2013) Selective atrial profibrotic signalling in mice and man. Cardiovasc Res 99(4):592-4

Laakmann S, Fortmüller L, Piccini I, Grote-Wessels S, Schmitz W, Breves G, Kirchhof P and Fabritz L (2013) Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice. Naunyn Schmiedebergs Arch Pharmacol 386(3):227-38

Fabritz L, Fortmüller L, Yu TY, Paul M and Kirchhof P (2012) Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial. Prog Biophys Mol Biol 110(2-3):340-6

Riley G, Syeda F, Kirchhof P and Fabritz L (2012) An introduction to murine models of atrial fibrillation. Front Physiol 3:296

Froese A, Breher SS, Waldeyer C, Schindler RFR, Nikolaev VO, Rinne S, Wischmeyer E, Schlueter J, Becher J, Simrick S, Vauti F, Kuhtz J, Meister P, Kreissl S, Torlopp A, Liebig SK, Laakmann S, Mueller TD, Neumann J, Stieber J, Ludwig A, Maier SK, Decher N, Arnold HH, Kirchhof P, Fabritz L* and Brand T* (2012) Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice. J Clin Invest 122(3):1119-30.

Fabritz L*, Hoogendijk M*, Scicluna BP, Van Amersfoorth SC, Fortmueller L, Wolf S, Laakmann S, Kreienkamp N, Piccini I, Breithardt G, Ruiz P, Witt H, Ebnet K, Wichter T, Levkau B, Franke WW, Pieperhoff S, de Bakker J, Coronel R and Kirchhof P (2011) Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice. J Am Coll Cardiol 57(6):740-50

Blana A, Kaese S, Fortmüller L, Laakmann S, Damke D, van Bragt K, Eckstein J, Piccini I, Kirchhefer U, Nattel S, Breithardt G, Carmeliet P, Carmeliet E, Schotten U, Verheule S, Kirchhof P and Fabritz L (2010) Knock-in gain-of-function sodium channel mutation prolongs atrial action potentials and alters atrial vulnerability. Heart Rhythm 7(12):1862-9

Fabritz L, Damke D, Emmerich M, Kaufmann SG, Theis K, Blana A, Fortmüller L, Laakmann S, Hermann S, Aleynichenko E, Steinfurt J, Volkery D, Riemann B, Kirchhefer U, Franz MR, Breithardt G, Carmeliet E, Schäfers M, Maier SKG, Carmeliet P and Kirchhof P (2010) Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. Cardiovascular Research 87(1):60-72

Wittköpper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T and El-Armouche (2010) A Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 120(2):617-26

For full publication lists see:


Principal Investigators
Professor Paulus Kirchhof
Dr Larissa Fabritz 
Dr Davor Pavlovic
Dr Dipak Kotecha 

Postdoctoral Researchers
Dr Winnie Chua
Dr Claire Hepburn
Dr Andrew Holmes
Dr Lisa Fortmeller - at University of Münster, Germany

Research Associates
Syeeda Nashitha Kabir
Clara Apicella

PhD Students and MD Students
Dannie Fobian
Sian-Marie O’Brian
Yanish Purmah
Jawad Qamar
Chris O’Shea
Simon Wells
Victor Cardoso
Sheabul Hoque

Former Group Members

Sebastian Fischbach
Sarah Hopkins
Marcel Kemper
Stefan Kuhlmann
Pushpa Patel
Dr Genna Riley
Dr Ewa Truchanowicz
Dr Eleni Vloumidi
Sabina Yasin
Ting Yu Yue
Dr Fahima Syeda
Dr Samantha Tull